What is Neocannbio?
Neocannbio operates at the intersection of advanced medical technology and cannabinoid-based drug development. Based in Seoul, South Korea, the company focuses on the rigorous scientific validation and clinical application of cannabis compounds to address unmet medical needs. By integrating proprietary extraction techniques with pharmaceutical-grade research, Neocannbio has established itself as a critical player in the evolving medical cannabis market. Its strategic focus remains on navigating complex regulatory environments while advancing therapeutic solutions that meet international standards for safety and efficacy.
How much funding has Neocannbio raised?
Neocannbio has raised a total of $7.4M across 1 funding round:
Series B
$7.4M
Series B (2023): $7.4M with participation from Donghoon Investment, Bilanx Investment, and Prologue Ventures
Key Investors in Neocannbio
Donghoon Investment
A prominent investment firm known for supporting high-growth technology and life sciences companies in the South Korean market.
Bilanx Investment
An investment group focused on strategic capital deployment within the healthcare and pharmaceutical sectors.
Prologue Ventures
A venture capital firm specializing in backing innovative biotech startups that demonstrate significant potential for clinical and commercial impact.
What's next for Neocannbio?
With the successful closure of this Series B round, Neocannbio is poised to transition from early-stage research into more intensive clinical trials and commercial scaling. The strategic allocation of these funds will likely prioritize the expansion of laboratory infrastructure and the recruitment of top-tier scientific talent to bolster its drug development capabilities. As the company continues to refine its therapeutic portfolio, the focus will shift toward securing international partnerships and navigating the regulatory pathways necessary for global market entry. This phase of growth is critical for Neocannbio as it seeks to transform its innovative research into tangible, market-ready medical solutions that address chronic health conditions on a global scale.
See full Neocannbio company page
